Tag
The NEONIPIGA phase 2 trial demonstrates durable survival and high pathological complete response rates with neoadjuvant nivolumab and ipilimumab in localized MSI-high gastric and GEJ adenocarcinoma, highlighting potential for organ-preserv
The multicenter PALACE-2 trial reports a 43.2% pathological complete response (pCR) with preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma and identifies baseline serum IL-6 as a po
PALACE‑2 reports that preoperative pembrolizumab combined with chemoradiotherapy produced a 43.2% pathologic complete response in resectable, locally advanced esophageal squamous cell carcinoma, with acceptable short‑term survival and a hig
A pooled analysis of two neoadjuvant nivolumab trials found that pathologic treatment effect >57% is associated with markedly improved 3‑year disease‑free and overall survival in HPV‑negative resectable HNSCC, suggesting pTE may be a use
The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectabl
The randomized phase 1b/2 Morpheus‑Melanoma trial found that tobemstomig (anti‑PD‑1/anti‑LAG‑3 bispecific) produced comparable pathological response rates to nivolumab plus ipilimumab with a substantially improved safety profile in resectab
